RxDoctor Payments Data

Chloe Steinshouer, MD

Pulmonary Disease · Wichita, KSNPI 1821218348

Payments from drug & device makers

$830in general payments, 2019–2025

Across 37 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$340
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$135
  • Boehringer Ingelheim$45
  • Electromed, Inc.$44
  • GSK$37
  • Pfizer$35
  • plus $194 from 10 others

What the payments were for

  • Food & beverage$830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$830 in reported general payments places this provider in the 30th percentile of 92 pulmonary disease providers in Kansas.

See all pulmonary disease providers in Kansas

Medicare billing

Part B allowed, 2024
$275,373
Medicare patients
612
Services billed
3,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter287$219,497
OfevNintedanib Esylate11$145,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol112$73,373
Breo ElliptaFluticasone/Vilanterol93$52,978
Dupixent PenDupilumab11$48,612
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr92$44,161
Incruse ElliptaUmeclidinium Bromide47$17,845
Spiriva RespimatTiotropium Bromide19$15,768
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$14,426
Albuterol Sulfate HfaAlbuterol Sulfate308$6,858
Advair HfaFluticasone Propion/Salmeterol14$6,550
Fluticasone-SalmeterolFluticasone Propion/Salmeterol56$6,093
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$5,014
SymbicortBudesonide/Formoterol Fumarate18$4,344
BreynaBudesonide/Formoterol Fumarate24$3,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$37$334,481519 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$45$176,01253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 92 pulmonary disease providers in Kansas.

Other pulmonary disease in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →